Nasopharyngeal Carcinoma Trial Landscape (June 2026)

Last updated: Jun 27, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

214
Recruiting
21
Phase 1
99
Phase 2
82
Phase 3
2
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for nasopharyngeal carcinoma trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Checkpoint inhibitor
69
Monoclonal antibody
28
Antibody-drug conjugate (ADC)
9
Chemotherapy
8
Bispecific antibody
8
Other / unclassified
6
Other inhibitor
3
Radioligand / radiopharmaceutical
1
Small-molecule inhibitor
1
Tyrosine kinase inhibitor (TKI)
1
Vaccine (other)
1
CAR-T cellular therapy
1

Recently Updated Trials

NCTPhaseTitleMechanism
NCT076674001, 2Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerCXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor)
NCT065322792Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerReactive oxygen species scavenger -- radioprotector (small molecule)
NCT06017895Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal CarcinomaUnknown mechanism
NCT065925992Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)PD-1 -- immune checkpoint blockade (monoclonal antibody)
NCT060292702Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerLAG-3 -- immune checkpoint inhibitor (monoclonal antibody)

Top Sponsors

SponsorRecruiting trials
Sun Yat-sen University75
Fujian Cancer Hospital9
Jiangxi Provincial Cancer Hospital7
Fudan University7
Zhejiang Cancer Hospital6

Geographic Distribution

Countries/regions with the most active trial sites for nasopharyngeal carcinoma. A multi-site trial is counted once per country/region.

China
151
United States
16
Singapore
9
Canada
4
South Korea
3
Australia
3
Spain
2
Italy
2
Hong Kong
2
Germany
2

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Jul 1, 2026NCT07667400Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerCXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor)
Jul 2026NCT07650266A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaPD-1 + CTLA-4 -- bispecific antibody
Apr 2026NCT07247201Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer PatientsNatural Killer cells -- adoptive cell therapy
Mar 31, 2026NCT07320963Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.HDAC + PD-1 + VEGFR -- HDAC inhibitor + immune checkpoint inhibitor + multi-kinase inhibitor
Mar 27, 2026NCT07625423Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck TumorsVEGF -- angiogenesis inhibitor via recombinant human endostatin gene delivery (gene therapy)
Aug 19, 2025NCT06479811[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersSomatostatin receptor (SSTR) -- targeted radioligand therapy using alpha-emitting radionuclide conjugated peptide
Jul 9, 2025NCT06802835EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaEGFR + PD-1 -- EGFR inhibition and immune checkpoint blockade (monoclonal antibodies)

You've seen the nasopharyngeal carcinoma landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.